The Science of Psychedelics for Mental Health | Dr. Robin Carhart-Harris
O epizodě podcastu
In this episode, my guest is Robin Carhart-Harris, PhD, distinguished professor of neurology and psychiatry at the University of California, San Francisco. He is one of leading researchers in the study of how psychedelics such as psilocybin, LSD and DMT can change the human brain and in doing so, be used to successfully treat various mental health challenges such as major depression, anorexia, obsessive-compulsive disorder (OCD) and addiction. He explains how psilocybin induces sustained changes in adaptive brain wiring and cognition. We discuss the key components of safe and effective psychedelic journeys, the role of hallucinations, the use of eye-masks to encourage people to “go internal,” and music, as well as what effective therapist support consists of before, during and after the session (also known as integration). We discuss micodosing vs. macrodosing and how researchers control for placebo effects in psychedelic research. We also discuss the current legal landscape around psychedelic therapies. Psychedelic therapies are fast emerging as powerful and soon-to-be mainstream treatments for medical health disorders, but they are not without their risks. As such, this episode ought to be of use to anyone interested in brain plasticity, mental health, psychology or neuroscience.
For the full show notes, visit hubermanlab.com.
Thank you to our sponsors
AG1 (Athletic Greens): https://athleticgreens.com/huberman
LMNT: https://drinklmnt.com/huberman
Waking Up: https://www.wakingup.com/huberman
Momentous: https://www.livemomentous.com/huberman
The Brain Body Contract
https://hubermanlab.com/tour
Timestamps
(00:00:00) Dr. Robin Carhart-Harris
(00:02:28) Sponsors: LMNT & Waking Up
(00:05:41) The Brain-Body Contract
(00:06:31) Origin of the Word: “Psychedelics”; Pharmacology
(00:12:05) Psychedelics & Revealing the Unconscious Mind, Psychotherapy
(00:17:32) Microdosing
(00:26:08) Psilocybin vs. Magic Mushroom Doses
(00:28:28) “Psychedelic-Therapy”, Music
(00:31:13) Sponsor: AG1
(00:36:26) Psychedelic Journey: “Trust, Let Go, Be Open”
(00:43:01) Negative Emotions, Fear & Psychedelics
(00:46:21) Global Functional Connectivity, Serotonin 2A Receptor; Subjective Experiences
(00:52:33) Pharmacology: Therapeutics without Psychedelic Effects; SSRIs
(00:58:45) Psilocybin & Depression; Long-Term Effects: Connectivity & Neuroplasticity
(01:10:26) Psilocybin Therapy & Anorexia
(01:12:56) Integration Phase & Psychedelic-Therapy; Meditation
(01:19:50) First-Time Psychedelic Use, “Entropic Brain Effect”, Neuroplasticity, Cognition
(01:30:16) Fibromyalgia & Psychedelic Treatment; MDMA Therapy & “Inner Healer”
(01:38:55) Placebo Response & Psychedelic Therapy
(01:41:39) LSD & Psychedelic-Therapy, Micro-Dose
(01:48:19) Combination Psilocybin-MDMA Therapy
(01:56:06) DMT “Rocketship” & Serotonin 2A Receptors; Ibogaine
(02:01:04) “Ego Dissolution”, Cocaine vs. Psychedelics; Relapses
(02:12:26) Psychedelics & Legal Landscape; Decriminalization
(02:17:54) MDMA, Trauma & Clinical Trials; Future Regulatory (FDA) Approval?
(02:23:25) Psilocybin & Current Clinical Trials
(02:28:41) Mental Health & Psychedelic Treatment, Safeguards, Paradigm Shift
(02:34:39) Zero-Cost Support, YouTube Feedback, Spotify & Apple Reviews, Sponsors, Momentous, Social Media, Neural Network Newsletter
Title Card Photo Credit: Mike Blabac
Disclaimer
In this episode, my guest is Robin Carhart-Harris, PhD, distinguished professor of neurology and psychiatry at the University of California, San Francisco. He is one of leading researchers in the study of how psychedelics such as psilocybin, LSD and DMT can change the human brain and in doing so, be used to successfully treat various mental health challenges such as major depression, anorexia, obsessive-compulsive disorder (OCD) and addiction. He explains how psilocybin induces sustained changes in adaptive brain wiring and cognition. We discuss the key components of safe and effective psychedelic journeys, the role of hallucinations, the use of eye-masks to encourage people to “go internal,” and music, as well as what effective therapist support consists of before, during and after the session (also known as integration). We discuss micodosing vs. macrodosing and how researchers control for placebo effects in psychedelic research. We also discuss the current legal landscape around psychedelic therapies. Psychedelic therapies are fast emerging as powerful and soon-to-be mainstream treatments for medical health disorders, but they are not without their risks. As such, this episode ought to be of use to anyone interested in brain plasticity, mental health, psychology or neuroscience.
For the full show notes, visit hubermanlab.com.
Thank you to our sponsors
AG1: https://athleticgreens.com/huberman
LMNT: https://drinklmnt.com/hubermanlab
Waking Up: https://wakingup.com/huberman
Momentous: https://livemomentous.com/huberman
Timestamps
(00:00:00) Dr. Robin Carhart-Harris
(00:02:28) Sponsors: LMNT & Waking Up
(00:05:41) The Brain-Body Contract
(00:06:31) Origin of the Word: “Psychedelics”; Pharmacology
(00:12:05) Psychedelics & Revealing the Unconscious Mind, Psychotherapy
(00:17:32) Microdosing
(00:26:08) Psilocybin vs. Magic Mushroom Doses
(00:28:28) “Psychedelic-Therapy”, Music
(00:31:13) Sponsor: AG1
(00:36:26) Psychedelic Journey: “Trust, Let Go, Be Open”
(00:43:01) Negative Emotions, Fear & Psychedelics
(00:46:21) Global Functional Connectivity, Serotonin 2A Receptor; Subjective Experiences
(00:52:33) Pharmacology: Therapeutics without Psychedelic Effects; SSRIs
(00:58:45) Psilocybin & Depression; Long-Term Effects: Connectivity & Neuroplasticity
(01:10:26) Psilocybin Therapy & Anorexia
(01:12:56) Integration Phase & Psychedelic-Therapy; Meditation
(01:19:50) First-Time Psychedelic Use, “Entropic Brain Effect”, Neuroplasticity, Cognition
(01:30:16) Fibromyalgia & Psychedelic Treatment; MDMA Therapy & “Inner Healer”
(01:38:55) Placebo Response & Psychedelic Therapy
(01:41:39) LSD & Psychedelic-Therapy, Micro-Dose
(01:48:19) Combination Psilocybin-MDMA Therapy
(01:56:06) DMT “Rocketship” & Serotonin 2A Receptors; Ibogaine
(02:01:04) “Ego Dissolution”, Cocaine vs. Psychedelics; Relapses
(02:12:26) Psychedelics & Legal Landscape; Decriminalization
(02:17:54) MDMA, Trauma & Clinical Trials; Future Regulatory (FDA) Approval?
(02:23:25) Psilocybin & Current Clinical Trials
(02:28:41) Mental Health & Psychedelic Treatment, Safeguards, Paradigm Shift
(02:34:39) Zero-Cost Support, YouTube Feedback, Spotify & Apple Reviews, Sponsors, Momentous, Social Media, Neural Network Newsletter
Disclaimer
Learn more about your ad choices. Visit megaphone.fm/adchoices
Popis podcastu
The Huberman Lab podcast is hosted by Andrew Huberman, Ph.D., a neuroscientist and tenured professor in the department of neurobiology, and by courtesy, psychiatry and behavioral sciences at Stanford School of Medicine. The podcast discusses neuroscience and science-based tools, including how our brain and its connections with the organs of our body control our perceptions, our behaviors, and our health, as well as existing and emerging tools for measuring and changing how our nervous system works.
Huberman has made numerous significant contributions to the fields of brain development, brain function, and neural plasticity, which is the ability of our nervous system to rewire and learn new behaviors, skills, and cognitive functioning. He is a McKnight Foundation and Pew Foundation Fellow and was awarded the Cogan Award, given to the scientist making the most significant discoveries in the study of vision, in 2017.
Work from the Huberman Laboratory at Stanford School of Medicine has been published in top journals, including Nature, Science, and Cell, and has been featured in TIME, BBC, Scientific American, Discover, and other top media outlets.
In 2021, Dr. Huberman launched the Huberman Lab podcast. The podcast is frequently ranked in the top 10 of all podcasts globally and is often ranked #1 in the categories of Science, Education, and Health & Fitness.